Evidence map›Paper›PMID 29562546›Full record

ReviewJournal of Alzheimer's disease : JAD2018

Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.

Ralph N Martins, Victor Villemagne, Hamid R Sohrabi, Pratishtha Chatterjee, Tejal M Shah, Giuseppe Verdile, Paul Fraser, Kevin Taddei, Veer B Gupta, Stephanie R Rainey-Smith and 27 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 129 citations in OpenAlex.

  1. Review
  2. Essential Oils fromCurrent pharmaceutical biotechnology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Understanding mechanisms of antioxidant action in health and disease.Nature reviews. Molecular cell biology · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 14 institutions in 4 countries.

Ralph N MartinsCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Victor VillemagneDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia.
Hamid R SohrabiCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Pratishtha ChatterjeeCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Tejal M ShahCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Giuseppe VerdileCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Paul FraserTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Canada.
Kevin TaddeiCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Veer B GuptaCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Stephanie R Rainey-SmithCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Eugene HoneCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Steve PedriniCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Wei Ling LimCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Ian MartinsCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Shaun FrostCSIRO Australian e-Health Research Centre/Health and Biosecurity, Perth, WA, Australia.
Sunil GuptaCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Sid O'BryantUniversity of North Texas Health Science Centre, Fort Worth, TX, USA.
Alan RembachFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
David AmesNational Ageing Research Institute, Parkville, VIC, Australia.
Kathryn EllisDepartment of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
Stephanie J FullerAustralian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
Belinda BrownAustralian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
Samantha L GardenerCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Binosha FernandoCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Prashant BharadwajCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Samantha BurnhamCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Simon M LawsCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Anna M BarronSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth WA, Australia.
Kathryn GoozeeDepartment of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.
Eka J WahjoepramonoCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Prita R AsihKaRa Institute of Neurological Diseases, Sydney NSW, Australia.
James D DoeckeCSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
Olivier SalvadoCSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
Ashley I BushFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Christopher C RoweDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia.
Samuel E GandyDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Colin L MastersCooperative Research Centre for Mental Health, Carlton, VIC, Australia.
Edith Cowan University · AUFlorey Institute of Neuroscience and Mental Health · AUCooperative Research Centre for Mental Health · AUThe University of Melbourne · AUAustralian Alzheimer’s Research Foundation · AUAustralian e-Health Research Centre · AUCSIRO Health and Biosecurity · AUIcahn School of Medicine at Mount Sinai · USMurdoch University · AUNanyang Technological University · SGThe University of Western Australia · AUUniversity of North Texas · USUniversity of Toronto · CAUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.

Indexed as

Alzheimer DiseaseAmyloidogenic ProteinsAnimalsAustraliaBiomarkersHumansOxidative StressAmyloidogenic ProteinsBiomarkersAlzheimer’s diseaseamyloidapolipoprotein EAβbiomarkerdementiaearly diagnosispreclinical

Identifiers

PMID29562546
PMCPMC5870031
OpenAlexW2794133158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.